Login to Your Account

Cephalon's Treanda Meets Its Endpoint In Pivotal NHL Study

By Jennifer Boggs

Thursday, October 25, 2007
A month after filing a new drug application for Treanda in chronic lymphocytic leukemia, Cephalon Inc. said the drug met its endpoint in a pivotal trial in indolent non-Hodgkin's lymphoma patients who are refractory to rituximab. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription